1-15 of 113
The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis
MinuteCE®The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis
Mechanism-Based Targeting: Why APRIL Matters in IgAN
MinuteCE®Mechanism-Based Targeting: Why APRIL Matters in IgAN
Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
MinuteCE®Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
- advertisement
Emerging Evidence: IgAN Disease-Modifying Agents
MinuteCE®Emerging Evidence: IgAN Disease-Modifying Agents
Emerging Therapies in IgAN: Who Could Benefit the Most?
MinuteCE®Emerging Therapies in IgAN: Who Could Benefit the Most?
Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN
MinuteCE®Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN
Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
MinuteCE®Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
Inside the IgAN Clinic: Shared Decision-Making Into Practice
CME/CEInside the IgAN Clinic: Shared Decision-Making Into Practice
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
CME/CETargeting CKD-aP at the Source: Key Mechanisms and Treatments
- advertisement
Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
CME/CECase-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
CME/CENo Patient with CKD Left Behind! Emerging CKD Therapies in T1D
A New Paradigm in IgAN Management—Advancing Clinical Practice in the Era of Therapeutic Expansion
CME/CEA New Paradigm in IgAN Management—Advancing Clinical Practice in the Era of Therapeutic Expansion
